Summa Equity-backed Axion Biosystems, a live-cell assay systems, agreed to acquire CytoSMART, a live-cell imager capable of producing high-quality, whole-well brightfield or high-throughput fluorescence images of living cells. Financial terms were not disclosed. “Since Axion BioSystems’ inception, our focus has been on developing user-centric products that accelerate scientific discovery, with the specific goal of building innovative systems that monitor cellular activity without disturbing the underlying biology. The Maestro, our flagship bioelectronic assay (BEA) platform, has transformed neurological disease research over the past 14 years. Likewise, our most recent addition to the BEA portfolio is doing the same in groundbreaking fields like immunotherapy,” Tom O’Brien, Axion BioSystems President and CEO.